Showing results (51-60 of 715) with videos related to
Sort By:
Pageof 72
Clinical Lymphoma, Myeloma & Leukemia|May 15, 2015
Use of second- and third-generation tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia: an evolving treatment paradigmElias Jabbour, Hagop Kantarjian, Jorge CortesLancet (London, England)|August 23, 2021
Chronic myeloid leukaemiaJorge Cortes, Carolina Pavlovsky, Susanne SaußeleTargeted Oncology|April 4, 2009
Treatment selection after imatinib resistance in chronic myeloid leukemiaElias Jabbour, Jorge Cortes, Hagop KantarjianExpert Opinion on Drug Safety|November 28, 2023
A comparative safety review of targeted therapies for acute myeloid leukemiaMark Dalgetty, Christian Leurinda, Jorge CortesCurrent Opinion in Oncology|September 22, 2006
Novel tyrosine kinase inhibitors in chronic myelogenous leukemiaElias Jabbour, Jorge Cortes, Hagop KantarjianSeminars in Hematology|September 30, 2010
Chronic myeloid leukemia and second-generation tyrosine kinase inhibitors: when, how, and which one?Elias Jabbour, Hagop Kantarjian, Jorge CortesCore Evidence|August 10, 2010
Nilotinib for the treatment of chronic myeloid leukemia: An evidence-based reviewElias Jabbour, Jorge Cortes, Hagop KantarjianCurrent Treatment Options in Oncology|April 11, 2013
Chronic myeloid leukemia: overview of new agents and comparative analysisPreetesh Jain, Hagop Kantarjian, Jorge CortesSeminars in Hematology|September 30, 2010
Third-generation tyrosine kinase inhibitors and beyondAlfonso Quintás-Cardama, Hagop Kantarjian, Jorge CortesCurrent Oncology Reports|August 3, 2021
The Care of the Leukemic Patients in Times of SARS-CoV-2Nabin Raj Karki, Thuy Le, Jorge CortesPageof 72